Table 6.
Comparison of WS-TLG and PERCIST or EORTC in breast cancer skeletal metastatic lesions; fluctuated group
| Case No. | FDG studya | age | WS-TLG | PERCIST bone | EORTC bone | CT type | Comment | |
|---|---|---|---|---|---|---|---|---|
| 10 | Pre Tx | 61 | 254.7 | Intertrabecular | ||||
| 4M | 43.5 | PMR | Blastic | |||||
| 9M | 107.1 | PMD | Blastic | |||||
| 11 | Pre Tx | 38 | 15.5 | Lytic | ||||
| 6M | 0 | PMR | Mixed | |||||
| 1Y 1M | 4.6 | PMD new lesion | Lytic, increased | |||||
| 12 | Pre Tx | 67 | 13.6 | Mixed | ||||
| 6M | 0 | CMR | Blastic | |||||
| 1Y | 0 | CMR | Blastic | |||||
| 1Y 6M (pre-Tx) | 0 | CMR | Blastic | Tx regimen change | ||||
| (4M) | 1.0 | PMD new lesion | Mixed: blastic and intertrabecular | |||||
| 13 | Pre Tx | 59 | 73.4 | Mixed | ||||
| 10M (pre-Tx) | 80.2 | SMD | Mixed | Tx regimen change | ||||
| (1Y) | 0.4 | CMR | Blastic | |||||
| 14 | Pre Tx | 60 | 24.5 | Intertrabecular | ||||
| 8M | 0 | CMR | Mixed; intertrabecular and lytic | |||||
| 11M | 0 | PMR | Blastic | |||||
| 1Y 5M (pre Tx) | 3.8 | PMD | Blastic | Tx regimen change | ||||
| (1Y) | 12.8 | PMD | Blastic | |||||
| 15 | Pre Tx | 65 | 13.3 | Lytic | ||||
| 1Y (pre Tx) | 72.4 | PMD | Mixed | Tx regimen change | ||||
| (4M) | 0.1 | PMR | Mixed | |||||
| (9M) | 10.2 | PMD | Mixed | |||||
| (1Y) | 14.1 | SMD | Mixed | |||||
PERCIST PET response criteria in solid tumor, EORTC criteria developed by European Organization for Research and Treatment of Cancer, Tx treatment, CMR complete metabolic remission, PMR partial metabolic response, SMD stable metabolic disease, PMD progressive metabolic disease, WS-TLG whole skeletal total lesion glycolysis
aTime after commencement of treatment for skeletal metastasis. () means time after the change of therapy